The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease

Drugs and Aging

Volumn 32, Issue 7, 2015, Pages 537-547

  Deardorff, William James ^a   Feen, Eliahu ^a   Grossberg, George T ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; TACRINE; CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; ASSESSMENT OF HUMANS; ASSESSMENT SCALE COGNITIVE SUBSCALE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TERMINAL CARE; ENZYMOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY;

AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84938416296     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-015-0273-x     Document Type: Article

References (93)

1. Alzheimer's Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2014;10(2):e47–92. doi:10.1016/j.jalz.2014.02.001.
2. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80(19):1778–83.
3. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137–47.
4. Qaseem A, Snow V, Cross JT, Forciea MA, Hopkins R, Shekelle P, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148(5):370–8.
5. National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. London: National Institute for Health and Clinical Excellence (NICE); 2011.
6. Lanctôt KL, Rajaram RD, Herrmann N. Therapy for Alzheimer’s disease: how effective are current treatments? Ther Adv Neurol Disord. 2009;2(3):163–80.
7. Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol. 1994;51(1):41–5.
8. Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S51–6.
9. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379–97.
10. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA. 1994;271(13):992–8.
11. Blackard WG, Sood GK, Crowe DR, Fallon MB. Tacrine. A cause of fatal hepatotoxicity? J Clin Gastroenterol. 1998;26(1):57–9.
12. Aricept (donepezil) [package insert]. Woodcliff Lake: Eisai Inc., Revised May 2014. http://www.aricept.com/docs/pdf/aricept_PI.pdf. Accessed 21 Feb 2015.
13. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD001190.
14. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211–25.
15. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind study. Clin Ther. 2010;32(7):1234–51.
16. Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response. BMC Geriatr. 2013;13:56.
17. Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, et al. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2012;27(6):421–32.
18. Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer’s disease: drug profile and clinical guidelines. CNS Neurosci Ther. 2013;19(5):294–301.
19. Schwartz LM, Woloshin S. How the FDA forgot the evidence: the case of donepezil 23 mg. BMJ. 2012;344:e1086.
20. Administrative and correspondence documents. In: FDA Drug Approval Package. 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000Admincorres.pdf. Accessed 21 Feb 2015.
21. Medical review(s). In: FDA Drug Approval Package. 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf. Accessed 21 Feb 2015.
22. Summary review. In: FDA Drug Approval Package. 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000SumR.pdf. Accessed 21 Feb 2015.
23. Exelon (rivastigmine) [package insert]. East Hanover: Novartis Pharmaceutical Corporation, Revised Oct 2013. https://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf. Accessed 21 Feb 2015.
24. Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2013;52(4):225–41.
25. Birks JS, Grimley EJ. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2015. doi:10.1002/14651858.CD001191.pub3.
26. Exelon Patch (rivastigmine) [package insert]. East Hanover: Novartis Pharmaceutical Corporation, Revised July 2013. https://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf. Accessed 21 Feb 2015.
27. Small G, Dubois B. A review of compliance to treatment in Alzheimer’s disease: potential benefits of a transdermal patch. Curr Med Res Opin. 2007;23(11):2705–13.
28. Boada M, Arranz FJ. Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer’s disease treated with rivastigmine. Dement Geriatr Cogn Disord. 2013;35(1–2):23–33.
29. Articus K, Baier M, Tracik F, Kühn F, Preuss UW, Kurz A. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer’s disease. Int J Clin Pract. 2011;65(7):790–6.
30. Winblad B, Grossberg G, Frölich L, Farlow M, Zechner S, Nagel J, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14–22.
31. Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer’s disease: a retrospective analysis. Dement Geriatr Cogn Disord. 2010;29(5):406–12.
32. Alva G, Grossberg GT, Schmitt FA, Meng X, Olin JT. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. Int J Geriatr Psychiatry. 2011;26(4):356–63.
33. Winblad B, Kawata AK, Beusterien KM, Thomas SK, Wimo A, Lane R, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Geriatr Psychiatry. 2007;22(5):485–91.
34. 2) in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;33(5):341–53.
35. Molinuevo JL, Frölich L, Grossberg GT, Galvin JE, Cummings JL, Krahnke T, et al. Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch. Alzheimers Res Ther. 2015;7(1):9.
36. Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M. A, 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer’s dementia. CNS Neurosci Ther. 2013;19(10):745–52.
37. Farlow MR, Grossberg G, Gauthier S, Meng X, Olin JT. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer’s disease. Curr Med Res Opin. 2010;26(10):2441–7.
38. Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Velting DM. A 24-week, open-label extension study to investigate the long-term safety, tolerability, and efficacy of 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2015;29(2):110–6.
39. Razadyne (galantamine) [package insert]. Titusville: Janssen Pharmaceuticals, Inc., Revised July 2013. http://www.razadyneer.com/sites/default/files/shared/pi/razadyne_er.pdf. Accessed 21 Feb 2015.
40. Lilienfeld S. Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002;8(2):159–76.
41. Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;1:CD001747.
42. Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease. Neuropsychiatr Dis Treat. 2014;10:391–401.
43. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593.
44. Herrmann N, Chau SA, Kircanski I, Lanctôt KL. Current and emerging drug treatment options for Alzheimer’s disease: a systematic review. Drugs. 2011;71(15):2031–65.
45. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2004;75(5):677–85.
46. Atri A, Rountree SD, Lopez OL, Doody RS. Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer’s disease: comparison of efficacy and effectiveness studies. Neurodegener Dis. 2012;10(1–4):170–4.
47. Rountree SD, Atri A, Lopez OL, Doody RS. Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement. 2013;9(3):338–45.
48. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1(2):7.
49. Wattmo C, Wallin Å, Londos E, Minthon L. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Dis Assoc Disord. 2011;25(1):63–72.
50. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SL, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169(9):867–73.
51. Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Med. 2009;6(9):e1000157.
52. Hernandez RK, Farwell W, Cantor MD, Lawler EV. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. J Am Geriatr Soc. 2009;57(11):1997–2003.
53. Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc. 2011;59(6):1019–31.
54. Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs Aging. 2010;27(6):435–49.
55. Parsons C, McCorry N, Murphy K, Byrne S, O’Sullivan D, O’Mahony D, et al. Assessment of factors that influence physician decision making regarding medication use in patients with dementia at the end of life. Int J Geriatr Psychiatry. 2014;29(3):281–90.
56. Tjia J, Briesacher BA, Peterson D, Liu Q, Andrade SE, Mitchell SL. Use of medications of questionable benefit in advanced dementia. JAMA Intern Med. 2014;174(11):1763–71.
57. Weschules DJ, Maxwell TL, Shega JW. Acetylcholinesterase inhibitor and N-methyl-d-aspartic acid receptor antagonist use among hospice enrollees with a primary diagnosis of dementia. J Palliat Med. 2008;11(5):738–45.
58. Parsons C, Briesacher BA, Givens JL, Chen Y, Tjia J. Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia. J Am Geriatr Soc. 2011;59(7):1253–9.
59. Shega JW, Ellner L, Lau DT, Maxwell TL. Cholinesterase inhibitor and N-methyl-d-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors. J Palliat Med. 2009;12(9):779–83.
60. Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother. 2009;7(2):74–83.
61. Namenda (memantine) [package insert]. St. Louis: Forest Pharmaceuticals, Inc., Revised Oct 2013. http://pi.actavis.com/data_stream.asp?product_group=1901&p=pi&language=E. Accessed 21 Feb 2015.
62. Bassil N, Thaipisuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimer’s disease. Expert Opin Pharmacother. 2010;11(10):1765–71.
63. Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox Res. 2013;24(3):358–69.
64. Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20–7.
65. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Group MM-M-S. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83–9.
66. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903.
67. Choi SH, Park KW, Na DL, Han HJ, Kim EJ, Shim YS, et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer’s disease: a multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin. 2011;27(7):1375–83.
68. Grossberg GT, Manes F, Allegri RF, Gutiérrez-Robledo LM, Gloger S, Xie L, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs. 2013;27(6):469–78.
69. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–24.
70. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014;311(1):33–44.
71. Patel L, Grossberg GT. Combination therapy for Alzheimer’s disease. Drugs Aging. 2011;28(7):539–46.
72. Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement. 2013;9(3):326–31.
73. Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5(1):6.
74. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review. BMJ Open. 2012;2:e000917. doi:10.1136/bmjopen-2012-000917.
75. Matsunaga S, Kishi T, Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer’s disease: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2014;. doi:10.1093/ijnp/pyu115.
76. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209–21.
77. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600–7.
78. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet. 2004;363(9427):2105–15.
79. Holmes C, Burns A, Passmore P, Forsyth D, Wilkinson D. AD2000: design and conclusions. Lancet. 2004;364(9441):1213–4 (author reply 6–7).
80. Schneider LS. AD2000: donepezil in Alzheimer’s disease. Lancet. 2004;363(9427):2100–1.
81. Silver G, Kay R, Phillips R. A critical analysis of the AD2000 study. In: Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease. NICE. 2006. https://www.nice.org.uk/guidance/ta111/documents/appendix-a-a-critical-analysis-of-the-ad2000-study2. Accessed 22 April 2015.
82. Namenda XR (memantine) [package insert]. St. Louis: Forest Pharmaceuticals, Inc., Revised Sept 2014. http://pi.actavis.com/data_stream.asp?product_group=1902&p=pi&language=E. Accessed 21 Feb 2015.
83. Namzaric (memantine/donepezil) [package insert]. St. Louis: Forest Pharmaceuticals, Inc., Revised Dec 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206439lbl.pdf. Accessed 21 Feb 2015.
84. Singh I, Grossberg GT. Critical appraisal and role of memantine extended-release in the management of Alzheimer’s disease. Degener Neurol Neuromuscul Dis. 2011;1:9–13.
85. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev. 2003;9(3):275–308.
86. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheime’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.
87. Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19(8):707–14.
88. Sasaki S, Horie Y. The effects of an uninterrupted switch from donepezil to galantamine without dose titration on behavioral and psychological symptoms of dementia in Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2014;4(2):131–9.
89. Spalletta G, Caltagirone C, Padovani A, Sorbi S, Attar M, Colombo D, et al. Cognitive and affective changes in mild to moderate Alzheimer’s disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study. PLoS One. 2014;9(2):e89216.
90. Cagnin A, Cester A, Costa B, Ermani M, Gabelli C, Gambina G, et al. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer’s disease. Neurol Sci. 2015;36(3):457–63.
91. Han HJ, Lee JJ, Park SA, Park HY, Kim JE, Shim YS, et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer’s disease. J Clin Neurol. 2011;7(3):137–42.
92. Massoud F, Desmarais JE, Gauthier S. Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatr. 2011;23(3):372–8.
93. Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging. 2006;10(5):417–29.